Instrument Inactif

Communiqués Ariad Pharmaceuticals, Inc.

Actions

US04033A1007

Recherche biotechnologique et médicale

Cours en clôture Nasdaq
- ^USD	-

09/01/17	Takeda Pharmaceutical : rachète l'américain Ariad pour 5,2 milliards de dollars	RE
09/01/17	Takeda rachète l'américain Ariad pour $5,2 mds	RE

Communiqués

06/02/17	Ariad Pharmaceuticals : Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency	BU
03/02/17	Ariad Pharmaceuticals : Enters into Definitive Agreement to Be Acquired by Takeda for $5.2 Billion	PU
03/02/17	Ariad Pharmaceuticals : Takeda to Acquire ARIAD Pharmaceuticals, Inc.	PU
18/01/17	Ariad Pharmaceuticals : Acquisition May Not Be in the Best Interests of ARIA Shareholders	PR
13/01/17	Brower Piven Commences An Investigation Into The Proposed Sale Of ARIAD Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	BU
09/01/17	ARIAD PHARMACEUTICALS, INC. Rigrodsky & Long, P.A. Announces Investigation Of Buyout	BU
09/01/17	Ariad Pharmaceuticals : Enters into Definitive Agreement to Be Acquired by Takeda for $5.2 Billion	BU
09/01/17	Ariad Pharmaceuticals : Takeda to Acquire ARIAD Pharmaceuticals, Inc.	BU
03/01/17	Ariad Pharmaceuticals : to Present at the 35th Annual J.P. Morgan Healthcare Conference	BU
07/12/16	Ariad Pharmaceuticals : Investigational Medicine Brigatinib Demonstrated 15.6 Month Systemic Median Progression-Free Survival in ALTA Study	BU
06/12/16	Ariad Pharmaceuticals : Announces Data Presentations at American Society of Hematology Meeting	BU
05/12/16	Ariad Pharmaceuticals : Presents Updated Brigatinib Data with 18.4 Months Median Intracranial Progression Free Survival (PFS) in ALK+ NSCLC Patients with CNS Metastases at the World Conference on Lung Cancer	BU
02/12/16	Ariad Pharmaceuticals : to Host Webcast and Conference Call on Brigatinib Data Presentations at the World Conference on Lung Cancer	BU
29/11/16	Ariad Pharmaceuticals : Announces FDA Full Approval and Label Update for Iclusig® (ponatinib) Based on Long-Term Efficacy and Safety Data from Phase 2 PACE Clinical Trial	BU
16/11/16	Ariad Pharmaceuticals : Announces Data Presentations at the World Conference on Lung Cancer	BU
14/11/16	Ariad Pharmaceuticals : Announces Launch of Inaugural ALK+ Day During Lung Cancer Awareness Month	BU
09/11/16	Ariad Pharmaceuticals : Announces Phase 1/2 Trial Data on Investigational Drug Brigatinib Published in The Lancet Oncology	BU
07/11/16	Ariad Pharmaceuticals : Reports Third Quarter 2016 Financial Results	BU
02/11/16	Ariad Pharmaceuticals : to Present at the Jefferies 2016 London Healthcare Conference	BU
01/11/16	Ariad Pharmaceuticals : to Webcast Conference Call on Third Quarter 2016 Financial Results	BU
31/10/16	Ariad Pharmaceuticals : Announces U.S. Food and Drug Administration Acceptance of NDA Filing for Brigatinib	BU
26/10/16	Ariad Pharmaceuticals : Announces Publication of the Preclinical Profile of Brigatinib in the Journal Clinical Cancer Research	BU
20/10/16	Ariad Pharmaceuticals : Reaffirms Commitment to Discovering and Developing Treatments for Patients with Rare Cancers	BU
10/10/16	Ariad Pharmaceuticals : Presents Updated Long-Term Follow-up Results from the Phase 1/2 Trial on Investigational Drug Brigatinib at 2016 ESMO Meeting	BU
28/09/16	Ariad Pharmaceuticals : Announces Regulatory Approval for Iclusig® (ponatinib) in Japan	BU